vs
CATALYST PHARMACEUTICALS, INC.（CPRX）与GDEV Inc.（GDEV）财务数据对比。点击上方公司名可切换其他公司
CATALYST PHARMACEUTICALS, INC.的季度营收约是GDEV Inc.的1.3倍（$152.6M vs $119.9M），CATALYST PHARMACEUTICALS, INC.净利率更高（34.5% vs 13.9%，领先20.7%），GDEV Inc.同比增速更快（13.3% vs 7.6%）
Catalyst Pharmaceuticals是一家总部位于美国佛罗里达州科勒尔盖布尔斯的生物制药企业，专注于罕见病药物研发。核心产品包括用于治疗兰伯特-伊顿肌无力综合征（LEMS）的氨吡啶磷酸盐，商品名为Firdapse。该药物2018年11月获FDA批准，除原有成人适应症外，还可用于6岁及以上的LEMS儿童患者。
GDEV Inc.是一家游戏娱乐控股公司，在纳斯达克上市，总部位于塞浦路斯利马索尔。该公司前身为2014年成立的游戏公司Nexters，2023年6月改组为控股集团，是欧洲前五的独立移动游戏企业，旗下拥有Nexters Studio、Cubic Games、Royal Ark、Game Gears、Light Hour Games等工作室，分支机构分布在塞浦路斯、亚美尼亚、哈萨克斯坦等地。
CPRX vs GDEV — 直观对比
营收规模更大
CPRX
是对方的1.3倍
$119.9M
营收增速更快
GDEV
高出5.7%
7.6%
净利率更高
CPRX
高出20.7%
13.9%
损益表 — Q4 FY2025 vs Q2 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $152.6M | $119.9M |
| 净利润 | $52.7M | $16.6M |
| 毛利率 | 82.9% | — |
| 营业利润率 | 40.5% | 15.5% |
| 净利率 | 34.5% | 13.9% |
| 营收同比 | 7.6% | 13.3% |
| 净利润同比 | -5.8% | 13.0% |
| 每股收益（稀释后） | $0.40 | $0.90 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CPRXGDEV
| Q4 25 | $152.6M | — | ||
| Q3 25 | $148.4M | — | ||
| Q2 25 | $146.6M | $119.9M | ||
| Q1 25 | $141.4M | — | ||
| Q4 24 | $141.8M | — | ||
| Q3 24 | $128.7M | — | ||
| Q2 24 | $122.7M | $105.8M | ||
| Q1 24 | $98.5M | — |
净利润CPRXGDEV
| Q4 25 | $52.7M | — | ||
| Q3 25 | $52.8M | — | ||
| Q2 25 | $52.1M | $16.6M | ||
| Q1 25 | $56.7M | — | ||
| Q4 24 | $55.9M | — | ||
| Q3 24 | $43.9M | — | ||
| Q2 24 | $40.8M | $14.7M | ||
| Q1 24 | $23.3M | — |
毛利率CPRXGDEV
| Q4 25 | 82.9% | — | ||
| Q3 25 | 84.7% | — | ||
| Q2 25 | 85.9% | — | ||
| Q1 25 | 87.3% | — | ||
| Q4 24 | 84.7% | — | ||
| Q3 24 | 85.0% | — | ||
| Q2 24 | 87.4% | — | ||
| Q1 24 | 87.3% | — |
营业利润率CPRXGDEV
| Q4 25 | 40.5% | — | ||
| Q3 25 | 44.7% | — | ||
| Q2 25 | 45.2% | 15.5% | ||
| Q1 25 | 44.8% | — | ||
| Q4 24 | 44.3% | — | ||
| Q3 24 | 39.6% | — | ||
| Q2 24 | 44.2% | 14.4% | ||
| Q1 24 | 27.5% | — |
净利率CPRXGDEV
| Q4 25 | 34.5% | — | ||
| Q3 25 | 35.6% | — | ||
| Q2 25 | 35.6% | 13.9% | ||
| Q1 25 | 40.1% | — | ||
| Q4 24 | 39.4% | — | ||
| Q3 24 | 34.1% | — | ||
| Q2 24 | 33.2% | 13.9% | ||
| Q1 24 | 23.6% | — |
每股收益（稀释后）CPRXGDEV
| Q4 25 | $0.40 | — | ||
| Q3 25 | $0.42 | — | ||
| Q2 25 | $0.41 | $0.90 | ||
| Q1 25 | $0.45 | — | ||
| Q4 24 | $0.44 | — | ||
| Q3 24 | $0.35 | — | ||
| Q2 24 | $0.33 | $0.81 | ||
| Q1 24 | $0.19 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $709.2M | $41.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $954.3M | $-129.4M |
| 总资产 | $1.1B | $210.2M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CPRXGDEV
| Q4 25 | $709.2M | — | ||
| Q3 25 | $689.9M | — | ||
| Q2 25 | $652.8M | $41.6M | ||
| Q1 25 | $580.7M | — | ||
| Q4 24 | $517.6M | — | ||
| Q3 24 | $442.3M | — | ||
| Q2 24 | $375.7M | $50.8M | ||
| Q1 24 | $310.4M | — |
股东权益CPRXGDEV
| Q4 25 | $954.3M | — | ||
| Q3 25 | $920.2M | — | ||
| Q2 25 | $856.0M | $-129.4M | ||
| Q1 25 | $794.3M | — | ||
| Q4 24 | $727.6M | — | ||
| Q3 24 | $660.9M | — | ||
| Q2 24 | $608.7M | $-118.7M | ||
| Q1 24 | $561.4M | — |
总资产CPRXGDEV
| Q4 25 | $1.1B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $971.9M | $210.2M | ||
| Q1 25 | $908.9M | — | ||
| Q4 24 | $851.4M | — | ||
| Q3 24 | $772.0M | — | ||
| Q2 24 | $706.4M | $282.8M | ||
| Q1 24 | $646.7M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $44.9M | — |
| 自由现金流经营现金流 - 资本支出 | $44.9M | — |
| 自由现金流率自由现金流/营收 | 29.4% | — |
| 资本支出强度资本支出/营收 | 0.0% | — |
| 现金转化率经营现金流/净利润 | 0.85× | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流CPRXGDEV
| Q4 25 | $44.9M | — | ||
| Q3 25 | $32.4M | — | ||
| Q2 25 | $71.3M | — | ||
| Q1 25 | $60.0M | — | ||
| Q4 24 | $70.9M | — | ||
| Q3 24 | $72.9M | — | ||
| Q2 24 | $64.1M | — | ||
| Q1 24 | $31.9M | — |
自由现金流CPRXGDEV
| Q4 25 | $44.9M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $71.3M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $70.8M | — | ||
| Q3 24 | $72.6M | — | ||
| Q2 24 | $64.1M | — | ||
| Q1 24 | $31.7M | — |
自由现金流率CPRXGDEV
| Q4 25 | 29.4% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 48.6% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 49.9% | — | ||
| Q3 24 | 56.4% | — | ||
| Q2 24 | 52.3% | — | ||
| Q1 24 | 32.2% | — |
资本支出强度CPRXGDEV
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.1% | — | ||
| Q3 24 | 0.2% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.2% | — |
现金转化率CPRXGDEV
| Q4 25 | 0.85× | — | ||
| Q3 25 | 0.61× | — | ||
| Q2 25 | 1.37× | — | ||
| Q1 25 | 1.06× | — | ||
| Q4 24 | 1.27× | — | ||
| Q3 24 | 1.66× | — | ||
| Q2 24 | 1.57× | — | ||
| Q1 24 | 1.37× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CPRX
| Firdapse | $97.6M | 64% |
| Agamree | $35.3M | 23% |
| Fycompa | $19.6M | 13% |
GDEV
暂无分部数据
